| Old Articles: <Older 21651-21660 Newer> |
|---|
 |
The Motley Fool
March 20, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Accredited Home Lenders... Newcastle Investment... NovaStar Financial... Fremont General... American Oriental Bioengineering...   |
The Motley Fool
March 20, 2007
David Lee Smith |
Freeport Seals the Deal Freeport-McMoRan Copper & Gold has completed the acquisition of Phelps Dodge, tripling its size in the process. This combined company should be on investors' radar screen. |
The Motley Fool
March 20, 2007
Rick Aristotle Munarriz |
Searching for the Anti-Antioco Will the new CEO help Blockbuster build on the success of Total Access? It all sounds pretty bleak, yet the company's stock is on a tear. |
The Motley Fool
March 20, 2007
Emil Lee |
Susser Cuts Red Ink: Fool by Numbers The largest non-refining operator of convenience stores and gas stations in Texas released fourth-quarter and full-year 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
March 20, 2007
Rich Smith |
Deb Shops but Doesn't Drop The teen clothier has shed its post-earnings gains. Investors, take note. |
The Motley Fool
March 20, 2007
Tom Taulli |
BigBand Networks' Hot Numbers The video revolution powers BigBand's dizzying growth. The video-infrastructure company has doubled sales for each of the past four years. That was enough to get investors excited in the recent IPO. |
The Motley Fool
March 20, 2007
Tom Taulli |
Private Equity on Trial Delaware's court ruling on Netsmart's small buyout may have big implications for shareholders. |
The Motley Fool
March 20, 2007
Toby Shute |
Asta Lotta Debt! Debt purchaser Asta Funding buys a $6.9 billion portfolio. Why should investors care? |
The Motley Fool
March 20, 2007
Tom Taulli |
Agile: Slow and Steady Doesn't Win Agile Software keeps plodding along. Investors keep ignoring it. |
The Motley Fool
March 20, 2007
Brian Lawler |
A Slowdown at Endo The FDA delays a decision on expanding the label for one of Endo's drugs. Investors, take note. |
| <Older 21651-21660 Newer> Return to current articles. |
